Overview


Guanethidine, an antihypertensive medication, reduces the release of catecholamines such as norepinephrine. Guanethidine crosses the sympathetic nerve membrane using the same mechanism as norepinephrine (NET, uptake 1, and this are critical for its action). Once guanethidine enters the nerve, it is concentrated within transmitter vesicles where it replaces norepinephrine. Guanethidine may also decrease the amount of norepinephrine released, which can inhibit the release and accumulation of granules. Guanethidine used to be a standard for hypertension-resistant agents. It was used safely during pregnancy but is not available in the United States. For the quick control of hypertensive emergencies, it is still available in certain countries (e.g. UK). Guanethidine can be used intravenously to block nerves (Bier block), which is used to treat chronic pain due to complex regional pain syndrome. Side effects include exercise and postural hypotension, delayed or retrograde ejaculation, and diarrhea. Guanethidine can be transported via uptake 1 to the presynaptic terminus by norepinephrine transporter (NET). This allows it to potentiate exogenously administered norepinephrine by competing with it. It is found in norepinephrine transmitters' vesicles and replaces norepinephrine. This causes a gradual loss of norepinephrine in nerve endings. It blocks norepinephrine's release when it reaches the terminal. It does not affect spontaneous release.

Guanethidine is a neuroeffector that inhibits or interferes with the release and/or dissemination of norepinephrine. It does not act at the effector cells by inhibiting the association between norepinephrine and its receptors. Guanethidine is taken up by norepinephrine transportation and concentrated in transmitter vesicles instead of NE. This causes gradual depletion in nerve endings' NE stores. Guanethidine blocks noradrenaline's release at the nerve terminal in response to an attack potential. Guanethidine, unlike ganglionic blocking drugs, suppresses the same responses mediated via alpha- and beta-adrenergic receptors. However, it does not cause parasympathetic blockade. Guanethidine reduces blood pressure in the supine posture due to sympathetic blockade. This results in a modest decrease in cardiac output and peripheral resistance. Guanethidine further lowers blood pressure by decreasing vasoconstriction, which is normal due to reflex sympathetic nerve activity when the upright position is assumed. This reduces venous return as well as cardiac output. The main driver of the guanethidine industry is an increase in stroke and hypertension cases. Hypertension has been exacerbated by the increased consumption of unhealthy and unbalanced food, irregular work hours, and poor sleep. Globally, hypertension and stroke cases are also increasing due to an increase in the elderly population. The availability of substitutes can limit the market. There are many antihypertensive medications on the market, and the most popular are thiazide diuretics. This inhibits the growth of the guanethidine industry. Investors are attracted to market growth by the current pandemic.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Guanethidine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Guanethidine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Merck & Co Inc
  • Astrazeneca Plc
  • Daiichi Sankyo Company Limited
  • Johnson & Johnson
  • Pfizer Inc
  • Novartis Ag
  • Sanofi Sa
  • United Therapeutics
  • Ranbaxy Laboratories
  • Bayer Ag
  • Lupin Limited
  • Boehringer Engelheim Gmbh

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Tablet
  • Eye Drops

By Application

  • Pharmaceutical Industry
  • Others

By End User

  • Hospitals
  • Drug Stores
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Guanethidine Market By Type, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Guanethidine Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Guanethidine Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Guanethidine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Guanethidine Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tablet
        2. Eye Drops

  • 8.   Guanethidine Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical Industry
        2. Others

  • 9.   Guanethidine Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Drug Stores
        3. Others

  • 10.   North America Guanethidine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Guanethidine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Guanethidine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Guanethidine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Merck Co Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Astrazeneca Plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Daiichi Sankyo Company Limited
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Johnson & Johnson
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis Ag
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Sanofi Sa
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. United Therapeutics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Ranbaxy Laboratories
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Bayer Ag
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11.Lupin Limited
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12.Boehringer Engelheim Gmbh
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients